Pharmaceutical manufacturer for Vortioxetine

Situated in Hyderabad, India, Symed Labs Ltd is a prominent and innovative producer of Active Pharmaceutical Ingredients (APIs) & a comprehensive solution provider for the pharmaceutical sector for chemistry related services. Symed labs has autonomously created processes for more than fifty APIs across various therapeutic categories in the laboratory and upscaled them to plant, as well as vending them to over 600 clients in 30 nations in the regulated and less regulated markets

Dipharma is a global Contract Development and Manufacturing Organisation (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients, with more than 500 employees, 4 cGMP plants and commercial offices in Italy, U.S.A. and China. We put our heart and soul into supporting our customers with a competitive and highly proactive approach, backed by 75 years of experience in safely handling hazardous chemical processes using state-of-the-art technologies. As a third-generation family-owned company, we have a long history of stability, commitment and financial solidity. We know how to deliver on creative innovation and we understand the critical importance of matching timelines, while operating in full respect of international regulations, Intellectual Property and third-party patents.

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

MEGAFINE provides cutting-edge and comprehensive API solutions and is inspected by regulatory authorities including USFDA, EU-GMP, Australia-TGA, Canada-HC, Korea-MFDS, Japan-PMDA, and Mexico-COFEPRIS. This esteemed manufacturer specializes in high-quality APIs and Intermediates, serving both Innovators and Generic companies. With an impressive track record of 26 US-DMFs, 6 CEPs, and over 250 global regulatory filings, MEGAFINE has recently inaugurated a state-of-the-art API plant to meet its growing demand and expansion.

Embarking on a transformative journey over four decades, Morepen has consistently strived to embody an organization marked by discernible, impactful differences. Every action we undertake is imbued with a profound commitment to enrich the lives we touch. Nestled amidst the serene surroundings of Baddi, our cutting-edge manufacturing facility boasts a scientifically integrated complex housing 10 plants, each tailored to produce specific product lines. Driven by a relentless pursuit of innovation, Morepen's extensive research and development infrastructure, alongside our dedicated workforce, ensures the maintenance of stringent quality standards. With a robust global footprint, we export to over 80 countries, holding certifications from esteemed regulatory authorities such as USFDA, WHO GMP, and EU GMP.

Prague Scientific brings extensive expertise in the development, manufacturing, and distribution of pharmaceuticals. It leads in cost-effectiveness within urology, cardiology, oncology, and pain products, specializing in solids, hormones, and sterile products. Prague Scientific provides comprehensive services encompassing development, regulatory affairs, and pharmacovigilance. Operating from facilities located in Prague (Czech Republic), Bucharest (Romania), and Ankleshwar (India), the company transfers over 80 products annually and leverages its vast global regulatory knowledge. It collaborates with clients through dedicated and multifunctional teams to fulfill specific requirements.

Kimia Biosciences, established in 1993, specializes in the production of bulk drugs for various medical segments. With a strong focus on quality and advanced technologies, Kimia aims to achieve global recognition in the production of both APIs and FDFs, while maintaining ethical business practices. The state-of-the-art facilities at Village Bhondsi, Gurugram enable the production of a wide range of APIs. Additionally, Kimia plans to develop its own facilities for lifestyle segments, adhering to international regulatory standards, with the goal of delivering top-quality pharmaceutical products and support to both consumers and healthcare professionals.

Established in May 2012, this company is a wholly-owned subsidiary of Shandong Bestcomm Pharmaceutical CO., Ltd. It is situated in the Qihe Economic Development Zone, which is renowned as the 'Pearl of the Yellow River'. The company has constructed API pilot test, production base, and formulation production base in adherence to European, American, and global standards. Currently, there are 13 production lines for oral solid preparations, oral liquid preparations, and API. The company is also intensifying its efforts in establishing preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines, and an innovative drug R&D center.

Zhejiang Tiantai Pharmaceutical Co., Ltd. (listed), founded in June 1998, is specialized in R&D, manufacturing and sales of antifungal and antibiotics series featured APIs products including Clindamycin Hydrochloride, Clindamycin Phosphate and Amphotericin B, and the CRO&CDMO business of APIs. The company is one of the major manufacturers of Clindamycin Hydrochloride and Clindamycin Phosphate at home and abroad. Focusing on the big health industry, the company has built the traditional featured APIs and API CDMO&CRO business plate and synthetic biology drugs plate. Relying on the advantages of existing products, technologies, teams and platforms, the company become a low-cost, scaled, APIs-and-preparations integrated manufacturing base of featured generic drugs, and gradually developed towards the innovative drugs.